-
Something wrong with this record ?
Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program
JP. Barret, F. Podmelle, B. Lipový, HO. Rennekampff, H. Schumann, A. Schwieger-Briel, TR. Zahn, HR. Metelmann, . ,
Language English Country Netherlands
Document type Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial
- MeSH
- Administration, Cutaneous MeSH
- Surgical Wound drug therapy MeSH
- Adult MeSH
- Gels therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Burns therapy MeSH
- Re-Epithelialization * MeSH
- Aged MeSH
- Skin Transplantation * MeSH
- Triterpenes therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Randomized Controlled Trial MeSH
The clinical significance of timely re-epithelialization is obvious in burn care, since delayed wound closure is enhancing the risk of wound site infection and extensive scarring. Topical treatments that accelerate wound healing are urgently needed to reduce these sequelae. Evidence from preliminary studies suggests that betulin can accelerate the healing of different types of wounds, including second degree burns and split-thickness skin graft wounds. The goal of this combined study program consisting of two randomized phase III clinical trials in parallel is to evaluate whether a topical betulin gel (TBG) is accelerating re-epithelialization of split-thickness skin graft (STSG) donor site wounds compared to standard of care. Two parallel blindly evaluated, randomised, controlled, multicentre phase III clinical trials were performed in adults undergoing STSG surgery (EudraCT nos. 2012-003390-26 and 2012-000777-23). Donor site wounds were split into two equal halves and randomized 1:1 to standard of care (a non-adhesive moist wound dressing) or standard of care plus TBG consisting of 10% birch bark extract and 90% sunflower oil (Episalvan, Birken AG, Niefern-Oeschelbronn, Germany). The primary efficacy assessment was the intra-individual difference in time to wound closure assessed from digital photographs by three blinded experts. A total of 219 patients were included and treated in the two trials. Wounds closed faster with TBG than without it (15.3 vs. 16.5 days; mean intra-individual difference=-1.1 days [95% CI, -1.5 to -0.7]; p<0.0001). This agreed with unblinded direct clinical assessment (difference=-2.1 days [95% CI, -2.7 to -1.5]; p<0.0001). Adverse events possibly related to treatment were mild or moderate and mostly at the application site. TBG accelerates re-epithelialization of partial thickness wounds compared to the current standard of care, providing a well-tolerated contribution to burn care in practice.
Birken AG Streiflingsweg 11 75223 Niefern Öschelbronn Germany
Catholic University of Applied Sciences Karlstrasse 36 79104 Freiburg Germany
Department of Dermatology University Medical Center Freiburg Hauptstrasse 7 79104 Freiburg Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025089
- 003
- CZ-PrNML
- 005
- 20230329093437.0
- 007
- ta
- 008
- 180709s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.burns.2017.03.005 $2 doi
- 035 __
- $a (PubMed)28400148
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Barret-Nerín, Juan Pedro, $u Department of Plastic Surgery and Burns, University Hospital Vall d'Hebron, Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: jpbarret@vhebron.net. $d 1967- $7 xx0284254
- 245 10
- $a Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program / $c JP. Barret, F. Podmelle, B. Lipový, HO. Rennekampff, H. Schumann, A. Schwieger-Briel, TR. Zahn, HR. Metelmann, . ,
- 520 9_
- $a The clinical significance of timely re-epithelialization is obvious in burn care, since delayed wound closure is enhancing the risk of wound site infection and extensive scarring. Topical treatments that accelerate wound healing are urgently needed to reduce these sequelae. Evidence from preliminary studies suggests that betulin can accelerate the healing of different types of wounds, including second degree burns and split-thickness skin graft wounds. The goal of this combined study program consisting of two randomized phase III clinical trials in parallel is to evaluate whether a topical betulin gel (TBG) is accelerating re-epithelialization of split-thickness skin graft (STSG) donor site wounds compared to standard of care. Two parallel blindly evaluated, randomised, controlled, multicentre phase III clinical trials were performed in adults undergoing STSG surgery (EudraCT nos. 2012-003390-26 and 2012-000777-23). Donor site wounds were split into two equal halves and randomized 1:1 to standard of care (a non-adhesive moist wound dressing) or standard of care plus TBG consisting of 10% birch bark extract and 90% sunflower oil (Episalvan, Birken AG, Niefern-Oeschelbronn, Germany). The primary efficacy assessment was the intra-individual difference in time to wound closure assessed from digital photographs by three blinded experts. A total of 219 patients were included and treated in the two trials. Wounds closed faster with TBG than without it (15.3 vs. 16.5 days; mean intra-individual difference=-1.1 days [95% CI, -1.5 to -0.7]; p<0.0001). This agreed with unblinded direct clinical assessment (difference=-2.1 days [95% CI, -2.7 to -1.5]; p<0.0001). Adverse events possibly related to treatment were mild or moderate and mostly at the application site. TBG accelerates re-epithelialization of partial thickness wounds compared to the current standard of care, providing a well-tolerated contribution to burn care in practice.
- 650 _2
- $a aplikace kožní $7 D000279
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a popálení $x terapie $7 D002056
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a gely $x terapeutické užití $7 D005782
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a reepitalizace $7 D062326
- 650 12
- $a transplantace kůže $7 D016038
- 650 _2
- $a chirurgická rána $x farmakoterapie $7 D000072836
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a triterpeny $x terapeutické užití $7 D014315
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Podmelle, Fred $u Department of Oral and Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, Ferdinand-Sauerbruch-Str. DZ7, 17475 Greifswald, Germany. Electronic address: podmelle@uni-greifswald.de.
- 700 1_
- $a Lipový, Břetislav $u Department for Burns and Reconstructive Surgery, University Hospital Brno, Jihlavská 20, Brno, Czech Republic.
- 700 1_
- $a Rennekampff, Hans-Oliver $u Division of Plastic and Aesthetic Surgery, Burn Surgery, Klinikum Leverkusen, Am Gesundheitspark 11, 51375 Leverkusen, Germany.
- 700 1_
- $a Schumann, Hauke $u Catholic University of Applied Sciences, Karlstrasse 36, 79104 Freiburg, Germany; Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.
- 700 1_
- $a Schwieger-Briel, Agnes $u Department of Pediatric Dermatology, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland.
- 700 1_
- $a Zahn, Tobias R $u Birken AG (An Amryt Pharma Company), Streiflingsweg 11, 75223 Niefern-Öschelbronn, Germany.
- 700 1_
- $a Metelmann, Hans-Robert $u Department of Oral and Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, Ferdinand-Sauerbruch-Str. DZ7, 17475 Greifswald, Germany.
- 700 1_
- $a ,
- 773 0_
- $w MED00000977 $t Burns $x 1879-1409 $g Roč. 43, č. 6 (2017), s. 1284-1294
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28400148 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20230329093435 $b ABA008
- 999 __
- $a ok $b bmc $g 1317220 $s 1022010
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 43 $c 6 $d 1284-1294 $e 20170408 $i 1879-1409 $m Burns $n Burns $x MED00000977
- LZP __
- $a Pubmed-20180709